Fisher Asset Management LLC Sells 180,575 Shares of Edwards Lifesciences Co. (NYSE:EW)

Fisher Asset Management LLC reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,133,892 shares of the medical research company's stock after selling 180,575 shares during the quarter. Fisher Asset Management LLC owned 1.18% of Edwards Lifesciences worth $543,959,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $34,000. Operose Advisors LLC boosted its position in Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock worth $44,000 after acquiring an additional 452 shares during the period. SRS Capital Advisors Inc. grew its stake in shares of Edwards Lifesciences by 292.6% in the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company's stock worth $44,000 after purchasing an additional 474 shares in the last quarter. NBC Securities Inc. bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $52,000. Finally, ORG Partners LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth about $66,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.2 %

Shares of EW traded up $0.18 on Friday, hitting $85.24. The company's stock had a trading volume of 2,327,197 shares, compared to its average volume of 3,772,540. The firm's fifty day moving average price is $90.13 and its 200-day moving average price is $79.23. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm has a market capitalization of $51.37 billion, a price-to-earnings ratio of 36.75, a P/E/G ratio of 3.55 and a beta of 1.10. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,255 shares of the company's stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $85.59, for a total transaction of $620,955.45. Following the completion of the sale, the chief financial officer now owns 19,074 shares of the company's stock, valued at approximately $1,632,543.66. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at $388,801.62. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $85.59, for a total value of $620,955.45. Following the sale, the chief financial officer now owns 19,074 shares of the company's stock, valued at $1,632,543.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 237,749 shares of company stock worth $20,920,934. Corporate insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EW. Citigroup boosted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a research note on Wednesday, April 3rd. Evercore ISI reduced their price target on Edwards Lifesciences from $92.00 to $89.00 and set an "in-line" rating for the company in a report on Friday, April 26th. Stifel Nicolaus increased their price objective on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a "hold" rating in a report on Friday, April 26th. StockNews.com upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Monday. Finally, Mizuho increased their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a "buy" rating in a research note on Thursday, April 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $92.71.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.